Mechanisms of skin toxicity of paclitaxel: An in vitro preclinical assessment.

  1. Perez-Fidalgo, Jose Alejandro 2
  2. Estornut Navarro, Cristina 1
  3. Sanz Garcia, Celia 6
  4. Perez-Leal, Martin 1
  5. Poveda Ferriols, Jesus 7
  6. Cervantes, Andres 4
  7. Milara Paya, Javier 5
  8. Cortijo Gimeno, Julio 3
  1. 1 Department of Pharmacology. Medical School. University of Valencia, Valencia, Spain;
  2. 2 Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain;
  3. 3 Department of Pharmacology. Medical School University of Valencia. Research and Docent Unit of the Consorcio Hospital General of Valencia., Valencia, Spain;
  4. 4 Biomedical Research Institute Incliva, University of Valencia, Department of Medical Oncology, Valencia, Spain;
  5. 5 Department of Pharmacology. Consorcio Hospital General of Valencia. Medical School of the University Jaume I of Castellon., Valencia, Spain;
  6. 6 Medical School. University Jaume I of Castellon, Castellon, Spain;
  7. 7 Department of Oncology. Hospital Clinico Universitario de Valencia., Valencia, Spain;
Journal:
Journal of Clinical Oncology

ISSN: 0732-183X 1527-7755

Year of publication: 2020

Volume: 38

Issue: 15_suppl

Pages: e15511-e15511

Type: Article

DOI: 10.1200/JCO.2020.38.15_SUPPL.E15511 GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Journal of Clinical Oncology

Abstract

Background: Paclitaxel skin toxicity is a frequent side effect extensively evaluated in the clinical setting. However little is known about the preclinical mechanisms that lead to this toxicity. The endpoint of this study was to analyse the cutaneous mechanisms that drive paclitaxel toxicity in a preclinical model. Methods: Primary human keratinocytes were co-cultured with human dermal fibroblast in collagen gel under air-liquid interface conditions to generate a multilayered 3D epidermis. Paclitaxel was added to 3D epidermis at 0.3 µM, 3 µM and 30 µM and total RNA and protein was extracted after 24h of incubation. Markers of cell senescence (p21 and p53), anti-apoptotic mediators (Bcl-2), skin elasticity (tropoelastin ELN, collagen type I and fibronectin), hidratation (aquaporin 3 AQP3), oxidative stress (NOX4), antioxidant (SOD1, Nrf2), and angiogenic markers (VEGFR, eNOS) were evaluated by RT-PCR and western blot. NfKB phosphorylation was measured by western blot and inflammatory citokines IL1α, IL-6 and IL-8 were measured in cultured supernatants by ELISA. Human primary melanocytes were cultured and stimulated with paclitaxel to measure melanogenesis through the expression of of TYR, TYRP1 and DCT genes. The effect of paclitaxel on skin endothelial cell angiogenesis was measured by endothelial tube formation. Results: In human 3D keratinocytesPaclitaxel inhibited the expression of Bcl-2, and increased the expression of p53 and p21. The angiogenic markers VEGF and eNOS were decreased. The expression of oxidative stress marker NOX4 was increased and the anti-oxidant mediators Nrf2 and SOD1 were decreased. Markers of elasticity, collagen type I, fibronectin and FN1 were decreased as occurs with AQP3 hidratation marker. Paclitaxel increased the phosphorylation of NfkB and elevated the secretion of IL1α, IL-6 and IL-8 cytokines. In skin endothelial cells, paclitaxel reduced the endothelial tube formation. In melanocytes, paclitaxel increased skin pigmentation represented by the increase of RNA expression of TYR, TYRP1 and DCT genes. Conclusions: This preclinical 3D model showed that paclitaxel impacts on the expression of proteins related with angiogenics, elasticity and senescence in human kerantinocytes. Moreover higher doses of paclitaxel increased inflammation parameters and confirmed phototoxic and anti-angiogenenic effects. This preclinical model could be a valuable tool to assess skin toxicity of new antineoplastic agents.

Funding information

Funders

  • None